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Abstract
Aim: The inflammatory response, initiated by neutrophil and monocyte adhesion to endothelial
cells, is important in the pathogenesis of acute coronary syndromes. Platelets play an important
role in inflammatory process by interacting with monocytes and neutrophils. In this study, we
investigated the effect of tirofiban on the levels of cell adhesion molecules (soluble intercellular
adhesion molecule-1, sICAM-1, and vascular cell adhesion molecule-1, sVCAM-1) in patients with
unstable angina pectoris (AP).
Methods: Thirty-five patients with unstable AP (Group I), ten patients with stable AP (Group II)
and ten subjects who had angiographycally normal coronary arteries (Group III) were included the
study. Group I was divided into two subgroups for the specific treatment regimens: Group IA (n =
15) received tirofiban and Group IB (n = 20) did not. Blood samples for investigating the cell
adhesion molecules were drawn at zero time (baseline; 0 h) in all patients and at 72 h in Group I.
Results: The baseline levels of sICAM-1 and sVCAM-1 were higher in Group I than in Groups II
and III. They were higher in Group IA than in Group IB. However, the sICAM-1 and sVCAM-1
levels decreased significantly in Group IA after tirofiban infusion. In contrast, these levels remained
unchanged or were increased above the baseline value in Group IB at 72 h.
Conclusion:  The levels of cell adhesion molecules in patients with unstable AP decreased
significantly after tirofiban infusion. Inhibition of platelet function by specific glycoprotein IIb/IIIa
antagonists may decrease platelet-mediated inflammation and the ischemic end-point.
Background
The inflammatory response, initiated by neutrophil and
monocyte adhesion to endothelial cells, is important in
the pathogenesis of acute coronary syndromes, especially
unstable angina pectoris (AP) [1-3]. Soluble intercellular
adhesion molecule-1 (sICAM-1) and vascular cell
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adhesion molecule-1 (sVCAM-1) are expressed on
endothelial cell membranes and are responsible for the
attachment of neutrophils, monocytes and lymphocytes
[4-6]. sICAM-1 and sVCAM-1 are cell surface proteins
inducible by tumor necrosis factor-α, interferon-γ and
interleukin-1β [7,8].
Tirofiban blocks glycoprotein (GP) IIb/IIIa receptors and
thus prevents fibrinogen binding to platelets. The main
effect of GP IIb/IIIa inhibitors is their strong anti-platelet
effect, which has been clinically proven in large-scale ran-
domized trials [9-13]. Platelets play an important role in
inflammatory process by interacting with monocytes and
neutrophils [14]. In this study, we tested the effect of
tirofiban on the levels of cell adhesion molecules in
patients with unstable AP.
Methods
Patient population
Thirty-five patients with unstable AP (Group I), 10 with
stable AP (Group II) and 10 subjects who had angiograph-
ically normal coronary arteries (Group III) were included
in this study. Unstable AP was defined as a change in the
pattern of chest pain, or a new onset of symptoms typical
of myocardial ischemia, with or without ST-T wave
changes on the electrocardiogram and without positive
cardiac enzymes. Diagnosis of stable AP was based on sig-
nificant coronary artery disease documented by coronary
angiography, without recent change in the character, fre-
quency or severity of anginal pain. Group III comprised
10 subjects who underwent coronary angiography due to
suspicious or symptomatic positive exercise test findings
but had normal coronary arteries.
All Group I patients were treated with aspirin, clopidogrel,
a statin, parenteral nitrate, and sufficient unfractionated
heparin infusion to achieve an activated clotting time of
300–350 s through 72 h. Group I was divided into two
subgroups for the specific treatment regimens: Group IA
(n = 15) received tirofiban and Group IB (n = 20) received
no tirofiban. Tirofiban was administered as a 0.4 µg/kg
per min bolus over 30 min followed by continuous infu-
sion of 0.1 µg/kg per min for 72 h through an infusion
pump.
Exclusion criteria
Patients with acute or chronic inflammatory disease,
autoimmune disease, cancer, congestive heart failure,
renal failure, congenital hemorrhagic disease, thrombocy-
topenia, thrombocytosis, significant ST segment elevation
on ECG, significant increase in serum cardiac enzymes,
current use of anticoagulant drugs or use of steroid or anti-
inflammatory drugs within the last three months were
excluded from the study.
Working protocol
All patients gave informed consent. Blood samples for
sICAM-1 and sVCAM-1 were drawn at baseline (0 h) in all
patients and at 72 h in Group I. Medical stabilization was
recommended for >24 h before any coronary interven-
tion. All patients underwent coronary angiography to
determine the severity and extent of their coronary artery
disease and to plan their medical treatments before
discharge.
Determination of sICAM and sVCAM levels
Blood samples for assays were obtained from antecubital
vein and drawn into vacutainer clotted tubes. Sera were
obtained by centrifugation of the tubes at 3000 rpm for 10
min. Samples were storaged at -70°C. sICAM-1 and
sVCAM-1 concentrations were determined using enzyme-
linked immunosorbent assay kits according to the manu-
facturer's instructions (Bendor Met Systems Test Kits,
Vienna, Austria). Intra-assay coefficients of variation were
3.2%, 1.4% and 1.9% at sVCAM-1 concentrations of
460.0 ng/ml, 689.2 ng/ml and 1550.5 ng/ml respectively,
and 4.1%, 2.5% and 7.1% at sICAM-1 concentrations of
169.4 ng/ml, 378.2 ng/ml and 939.7 ng/ml respectively.
The overall intra-assay coefficients of variation were 3.1%
for sVCAM-1 and %4.1 for sICAM-1.
Statistical analysis
All analyses were univariate. Groups were compared using
chi square and Fisher's Exact test for nominal variables;
the Kruskall Wallis nonparametric ANOVA for categorical
variables; and the Mann Whitney U test for continuous
variables. Post-hoc group comparisons were done by the
Scheffe test. Values of p < 0.05 were considered signifi-




Mean age was similar in all groups. Male sex was domi-
nant in Group I. Female sex was dominant in Groups II
and III. Clinical characteristics of the study groups are
shown in Table 1. There were no significant differences
between Groups IA and IB in the following variables: age,
gender, diabetes mellitus, current smoker, hypertension,
body mass index, leukocyte count, erythrocyte sedimenta-
tion rate, serum total cholesterol, triglyceride, HDL-cho-
lesterol and LDL-cholesterol. Statistical comparisons of
possible confounders between the two acute coronary
syndrome groups are shown in Table 2.
Cell adhesion molecules
Baseline levels of sICAM-1 and sVCAM-1 were higher in
Groups IA and IB than in Groups II and III. Baseline levels
of these molecules were similar in Group II and III (Figure
1). Table 3 shows the statistical comparison of cellThrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/4
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Table 1: Characteristics of the study groups
Group IA (n = 15) Group IB (n = 20) Group II (n = 10) Group III (n = 10)
Mean age (yr) 57.7 ± 10.2 57.8 ± 8.7 53.3 ± 7.4 56.8 ± 11.8
Male sex (%) 86 90 40 40
DM (%) 13 25 0 0
Current smoker (%) 80 45 60 70
HT (%) 60 35 70 30
BMI 33.7 ± 6.8 28.9 ± 4.5 26.1 ± 2.5 26.3 ± 3.1
WBC (/mm3) 9044 ± 2097 8685 ± 2541 6200 ± 964 6530 ± 1240
ESR (mm/hr) 28.3 ± 16.2 22.4 ± 14 6.7 ± 1.9 8.5 ± 1.8
TC (mg/dl) 209.9 ± 69.1 181.2 ± 31.6 199.2 ± 46.5 200 ± 38.2
TG (mg/dl) 202 ± 120 156.8 ± 86.4 101.9 ± 32 113.6 ± 41.7
HDL-C (mg/dl) 40.5 ± 13 41.4 ± 9.9 32.8 ± 4.2 41.1 ± 9.8
LDL-C (mg/dl) 119 ± 47 109 ± 26.6 102.7 ± 24 107 ± 37.5
Extent of CAD
1 vessel (%) 0 2 07 00
2 vessel (%) 54 20 30 0
3 vessel (%) 46 60 0 0
Group IA: Patients with unstable angina pectoris and tirofiban infusion, Group IB: Patients with unstable angina pectoris but no tirofiban infusion, 
Group II: Patients with stable angina pectoris, Group III: patients with normal coronary angiography, DM: Diabetes mellitus, HT: Hypertension, 
BMI: Body mass index, WBC: White blood cell, ESR: Erythrocyte sedimentation rate, TC: Total cholesterol, TG: Triglyceride, HDL-C: High 
density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, CAD: Coronary artery disease.
Table 2: Statistical comparisons of possible confounders between the two acute coronary syndrome groups
Group IA (n = 15) Group IB (n = 20) Significance
Mean age (yr) 57.7 ± 10.2 57.8 ± 8.7 0,84c
Male sex (%) 86 90 0,60a
DM (%) 13 25 0.43a
Current smoker (%) 80 45 0.79a
HT (%) 60 35 0.18b
BMI 33.7 ± 6.8 28.9 ± 4.5 0.07c
WBC (/mm3) 9044 ± 2097 8685 ± 2541 0.49c
ESR (mm/hr) 28.3 ± 16.2 22.4 ± 14 0.11c
TC (mg/dl) 209.9 ± 69.1 181.2 ± 31.6 0.27c
TG (mg/dl) 202 ± 120 156.8 ± 86.4 0.37c
HDL-C (mg/dl) 40.5 ± 13 41.4 ± 9.9 0.27c
LDL-C (mg/dl) 119 ± 47 109 ± 26.6 0.73c
a = Fisher's exact test b = Chi square test c = Mann Whitney U test Group IA: Patients with unstable angina pectoris and tirofiban infusion, 
Group IB: Patients with unstable angina pectoris but no tirofiban infusion, DM: Diabetes mellitus, HT: Hypertension, BMI: Body mass index, 
WBC: White blood cell, ESR: Erythrocyte sedimentation rate, TC: Total cholesterol, TG: Triglyceride, HDL-C: High density lipoprotein 
cholesterol, LDL-C: Low density lipoprotein cholesterol.
Table 3: Statistical comparison of cell adhesion molecule levels among all groups
Cell adhesion molecule Group IA (n = 15) Group IB (n = 20) Group II (n = 10) Group III (n = 10) Post hoc*
sICAM-1 Baseline ng/ml 633.37 ± 136.8 450.0 ± 138.9 196.4 ± 100.2 93.6 ± 43.6 1 > 2 > (3 = 4)
sVCAM-1 Baseline ng/ml 390.3 ± 96.9 283.9 ± 75.5 162.0 ± 52.5 105.0 ± 33.5 1 > 2 > (3 = 4)
* Scheffe test Group IA: Patients with unstable angina pectoris and tirofiban infusion, Group IB: Patients with unstable angina pectoris but no 
tirofiban infusion, Group II: Patients with stable angina pectoris, Group III: patients with normal coronary angiography,sICAM-1: Soluble 
intercellular adhesion molecule-1, sVCAM-1: Soluble vascular cell adhesion molecule-1.Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/4
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adhesion molecules levels among the all groups.
Although the baseline levels were higher in Group IA than
in Group IB, sICAM-1 and VCAM-1 decreased signifi-
cantly in Group IA after tirofiban infusion (Figure 2). In
contrast, sICAM-1 and sVCAM-1 levels remained
unchanged or increased above baseline in Group IB at 72
h (Figure 3). Table 4 shows the statistical comparison of
cell adhesion molecule levels between the two acute coro-
nary syndrome groups.
Coronary angiography
Multivessel coronary artery disease was found in 100% of
Group IA and 80% of Group IB. Based on the coronary
angiographic results, 26.7% of Group IA patients were
treated by medical therapy, 53.3% PTCA and 20% CABG.
In Group IB, 25% of the patients were treated by medical
therapy, 50% PTCA and 25% CABG. These differences
between the two subgroups were not statistically signifi-
cant. The coronary angiographic results are shown in
Table 1.
Discussion
This study suggests that tirofiban infusion suppresses the
elevation of soluble cell adhesion molecule levels in
patients with unstable AP. Such patients were selected
because it was expected that inflammatory activities
would be triggered in their vascular systems.
The importance of inflammation in acute coronary syn-
dromes is well established. It is known that GP IIb/IIIa
antagonists inhibit platelet activation by blocking the
fibrinogen binding receptor [15]. However, can the clini-
cal improvements demonstrated in multi-central studies
be attributed solely to inhibition of platelet activation?
Platelets play an important role not only in the coagula-
tion system but also in the inflammatory response [16-
18]. Platelet activation can increase inflammation
through several mechanisms. Platelets release a wide
range of growth factors and inflammatory mediators from
intracellular storage organelles. Products of activation
may aid neutrophil accumulation and enhance inflamma-
tion. Activated leukocytes and platelets potentate each
others' effects. The important mediators released by plate-
lets are P-selectin (CD62p), CD40p, platelet activating
factor, macrophage chemotactic factor-1, interleukin-1,
thrombospondin and fibronectin. These mediators are
rapidly expressed by activated platelets [19-24].
Levels of the cell adhesion molecules in all groups Figure 1
Levels of the cell adhesion molecules in all groups. Group IA: 
Patients with unstable angina pectoris and tirofiban infusion, 
Group IB: Patients with unstable angina pectoris but no 
tirofiban infusion, Group II: Patients with stable angina pec-
toris, Group III: patients with normal coronary angiography, 
sICAM-1: Soluble intercellular adhesion molecule-1, sVCAM-
1: Soluble vascular cell adhesion molecule-1.
Levels of the cell adhesion molecules in patients with unsta- ble angina pectoris who received tirofiban infusion Figure 2
Levels of the cell adhesion molecules in patients with unsta-
ble angina pectoris who received tirofiban infusion. sICAM-1: 
Soluble intercellular adhesion molecule-1, sVCAM-1: Soluble 
vascular cell adhesion molecule-1.Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/4
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Inhibition of platelet function by specific GP IIb/IIIa
antagonists may decrease plateletmediated inflammation.
Tirofiban may not only inhibit platelet activation but also
suppress inflammatory processes [25,26]. This effect is
not cross-reactivity; it can explain the antiinflammatory
properties of tirofiban.
In a group (IA) of high risk patients with unstable AP, the
high baseline levels of some cell adhesion molecules
(sICAM-1, sVCAM-1), significantly decrease after adding
tirofiban to the usual treatment of intravenous unfraction-
ated heparin, aspirin and others. In patients with UAP but
lower risk, the baseline values of sICAM-1 and sVCAM-1,
although higher than those of the Groups II and III, were
not affected by the treatment, that not includes tirofiban.
Inflammation, especially platelet-mediated, may be sup-
pressed and the ischemic end-point will be reduced after
GP IIb/IIIa antagonist therapy.
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